|
MechanismEGFR antagonists |
|
|
|
|
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.CH |
First Approval Date01 Dec 2003 |
|
|
|
|
|
|
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. |
First Approval Date20 Oct 1995 |
|
|
|
|
|
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.US |
First Approval Date18 Apr 1975 |
Safety Study of Bintrafusp alfa in Combination with Other Anti-cancer Therapies in Participants with Locally Advanced or Advanced Cervical Cancer
Safety Study of Bintrafusp alfa in Combination with Other Anti-cancer Therapies in Participants with Locally Advanced or Advanced Cervical Cancer
A Phase II Multicenter Randomized Open-Label Controlled Study of M7824 Versus Pembrolizumab as a First-line Treatment in Patients With PD-L1 Expressing Advanced Non-small Cell Lung Cancer
100 Clinical Results associated with Merck Biopharma Co., Ltd.
0 Patents (Medical) associated with Merck Biopharma Co., Ltd.
100 Deals associated with Merck Biopharma Co., Ltd.
100 Translational Medicine associated with Merck Biopharma Co., Ltd.